Last reviewed · How we verify
Tepotinib TF3
At a glance
| Generic name | Tepotinib TF3 |
|---|---|
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib (PHASE1)
- Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tepotinib TF3 CI brief — competitive landscape report
- Tepotinib TF3 updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI